Annals of Diagnostic Pathology
Volume 12, Issue 4 , Pages 283-285 , August 2008

HER-2 status in gastrointestinal stromal tumor

  • Lisandro Ferreira Lopes, MD
    • ,
  • Carlos E. Bacchi, MD, PhD

      Affiliations

    • Corresponding Author InformationCorresponding author. Consultoria em Patologia, Rua Major Leonidas Cardoso, 739, Botucatu, SP, Brazil 18602-010. Tel.: +55 14 3815 5989; fax: +55 14 3815 5989.

References 

  1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  2. Maguire HC, Greene MI. The neu (c-erbB-2) oncogene. Semin Oncol. 1989;16:148–155
  3. Tandon , Clark GM, Chamness GC, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989;7:1120–1128
  4. Gusterson , Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992;10:1049–1056
  5. Dougall WC, Qian X, Peterson NC, et al. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene. 1994;9:2109–2123
  6. Menard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci. 2004;61:2965–2978
  7. Johnson PH, Esteva FJ. The use of HER2 modulation in the adjuvant setting. Curr Oncol Rep. 2007;9:9–16
  8. Meric-Bernstam , Hung MC. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res. 2006;12:6326–6330
  9. Rubin BP. Gastrointestinal stromal tumours: an update. Histopathology. 2006;48:83–96
  10. Miettinen M, Lasota J. Gastrointestinal stromal tumours. Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466–1478
  11. Savage , Antman KH. Imatinib mesylate—a new oral targeted therapy. N Engl J Med. 2002;346:683–693
  12. Cai YC, Jiang Z, Vittimberga F, et al. Expression of transforming growth factor-alpha and epidermal growth factor receptor in gastrointestinal stromal tumours. Virchows Arch. 1999;435:112–115
  13. Tornillo L, Duchini G, Carafa V, et al. Patterns of gene amplification in gastrointestinal stromal tumors (GIST). Lab Invest. 2005;85:921–931
  14. Lanzafame S, Minutolo V, Caltabiano R, et al. About a case of GIST occurring during pregnancy with immunohistochemical expression of epidermal growth factor receptor and progesterone receptor. Pathol Res Pract. 2006;202:119–123
  15. Yoo NJ, Lee JW, Soung YH, et al. Mutational analysis of the epidermal growth factor receptor gene in gastrointestinal stromal tumors. J Korean Gastric Cancer Assoc. 2004;4:268–271
  16. Lopes LF, Bacchi CE. EGFR and gastrointestinal stromal tumor: an immunohistochemical and FISH study of 82 cases. Mod Pathol. 2007;20:990–994

PII: S1092-9134(08)00026-9

doi: 10.1016/j.anndiagpath.2008.02.007

Annals of Diagnostic Pathology
Volume 12, Issue 4 , Pages 283-285 , August 2008

Article Tools

* Image Usage & Resolution